KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Revenue (2016 - 2025)

Ionis Pharmaceuticals has reported Revenue over the past 17 years, most recently at $203.3 million for Q4 2025.

  • Quarterly results put Revenue at $203.3 million for Q4 2025, down 10.26% from a year ago — trailing twelve months through Dec 2025 was $493.7 million (down 29.99% YoY), and the annual figure for FY2025 was $943.7 million, up 33.83%.
  • Revenue for Q4 2025 was $203.3 million at Ionis Pharmaceuticals, up from $156.7 million in the prior quarter.
  • Over the last five years, Revenue for IONS hit a ceiling of $324.5 million in Q4 2023 and a floor of $2.0 million in Q2 2025.
  • Median Revenue over the past 5 years was $137.9 million (2022), compared with a mean of $150.2 million.
  • Biggest five-year swings in Revenue: soared 867.31% in 2021 and later tumbled 99.11% in 2025.
  • Ionis Pharmaceuticals' Revenue stood at $60.0 million in 2021, then skyrocketed by 153.15% to $151.9 million in 2022, then skyrocketed by 113.64% to $324.5 million in 2023, then tumbled by 30.18% to $226.6 million in 2024, then fell by 10.26% to $203.3 million in 2025.
  • The last three reported values for Revenue were $203.3 million (Q4 2025), $156.7 million (Q3 2025), and $2.0 million (Q2 2025) per Business Quant data.